Tech Company Financing Transactions
Cybrexa Therapeutics Funding Round
Cybrexa Therapeutics, based in New Haven, scored $13.4 million in funding from Connecticut Innovations, Cycle Capital and HighCape Partners.
Transaction Overview
Company Name
Announced On
6/21/2019
Transaction Type
Venture Equity
Amount
$13,400,000
Round
Series B
Proceeds Purpose
Proceeds from the financing will be used to advance Cybrexa's first clinical candidate CBX-11 (alphalex-rucaparib) into clinical development and to progress additional programs in its preclinical pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
395 Winchester Ave. 5 Science Park
New Haven, CT 06511
USA
New Haven, CT 06511
USA
Phone
Website
Email Address
Not Recorded
Overview
Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Kevin Didden
Chief Executive Officer
Per Hellsund
Chief Medical Officer
Arthur DeCillis
Chief Medical Officer
Peter Glazer
Chief Scientific Officer
Vishwas Paralkar
Co-Founder
Ranjit Bindra
Browse more venture capital transactions:
Prev: 6/21/2019: Engage3 venture capital transaction
Next: 6/21/2019: Rhumbix venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs